These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 7945430

  • 1. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1994 Oct 07; 48(7):1327-39. PubMed ID: 7945430
    [Abstract] [Full Text] [Related]

  • 2. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G.
    Biochem Pharmacol; 1996 Apr 12; 51(7):911-8. PubMed ID: 8651941
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM, Peters GJ.
    Biochim Biophys Acta; 2000 Mar 06; 1474(1):5-12. PubMed ID: 10699484
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun 06; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 5. Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
    Smitskamp-Wilms E, Pinedo HM, Veerman G, Ruiz van Haperen VW, Peters GJ.
    Eur J Cancer; 1998 May 06; 34(6):921-6. PubMed ID: 9797708
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

  • 8. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
    Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1993 Aug 17; 46(4):762-6. PubMed ID: 8363650
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.
    Cancer Res; 1992 Feb 01; 52(3):533-9. PubMed ID: 1732039
    [Abstract] [Full Text] [Related]

  • 11. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 01; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 12. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W.
    Cancer Chemother Pharmacol; 1991 Jan 01; 27(4):258-62. PubMed ID: 1998982
    [Abstract] [Full Text] [Related]

  • 13. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ.
    Eur J Cancer; 2000 Dec 01; 36(18):2420-9. PubMed ID: 11094319
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
    Heinemann V, Schulz L, Issels RD, Plunkett W.
    Semin Oncol; 1995 Aug 01; 22(4 Suppl 11):11-8. PubMed ID: 7481839
    [Abstract] [Full Text] [Related]

  • 16. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY, Hickey RJ, Abdel-Aziz W, Malkas LH.
    Cancer Chemother Pharmacol; 2000 Aug 01; 45(4):320-8. PubMed ID: 10755321
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V, Hertel LW, Grindey GB, Plunkett W.
    Cancer Res; 1988 Jul 15; 48(14):4024-31. PubMed ID: 3383195
    [Abstract] [Full Text] [Related]

  • 18. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.
    Smid K, Van Moorsel CJ, Noordhuis P, Voorn DA, Peters GJ.
    Int J Oncol; 2001 Jul 15; 19(1):157-62. PubMed ID: 11408937
    [Abstract] [Full Text] [Related]

  • 19. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM, Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):397-406. PubMed ID: 9933028
    [Abstract] [Full Text] [Related]

  • 20. A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
    Nishi R, Yamauchi T, Ueda T.
    Cancer Sci; 2006 Nov 15; 97(11):1274-8. PubMed ID: 17034368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.